RESUMEN
AIM: Premedication with antithyroid drugs (ATD) compared to patients not pretreated with ATD causes a higher failure rate of radioiodine therapy (RITh) or demands higher therapeutical dosage of radioiodine (RI). For clinical reasons and because of accelerated iodine metabolism in hyperthyreosis a compensated thyroid metabolism is desirable. Aim of this study was to investigate the influence of ATD on the biokinetics of RI in case of Graves' disease in order to improve RITh of patients pre-treated with ATD. METHODS: 385 consecutive patients who underwent RITh because of Graves' disease for the first time were included: Group A (n = 74): RITh under continuous medication with ATD; Group B (n = 111): Application of RI under continuous medication with ATD, in case of insufficient RI-uptake or shortened effective RI-half-life ATD were stopped 1-5 days after RITh; Group C (n = 200): ATD were stopped 2 days prior to RITh in all patients. We examined the influence of ATD on RI-uptake and effective RI-half-life as well as the absorbed dose achieved on the thyroid in dependence of thyroid volume and applied RI-dosage [TEQ--therapy efficiency quotient, (2)]. RESULTS: In the RI-pretest (all patients under ATD) the RI-uptake was comparable in all three groups. During RITh RI-uptake, effective RI-half-life and therefore the TEQ were significantly higher in Group C as compared to Groups A and B (p < 0.001, respectively). In Group B the medication with ATD was stopped in 61 of 111 cases 1-5 days after RITh. In this subgroup the effective RI-half-life increased from 4.4 +/- 1.7 d to 5.1 +/- 1.6 d after stopping of ATD (p = 0.001). CONCLUSION: Stopping of ATD 2 days prior to RITh leads to an increased efficiency of about 50% compared to RITh carried out under ATD and therefore to a clear reduction of radiation exposure to the rest of the body with equal absorbed doses of the thyroid. Stopping of ATD shortly after RITh increases efficiency in case of short effective RI-half-life, but it is inferior to stopping ATD 2 days prior to RITh.
Asunto(s)
Antitiroideos/farmacocinética , Antitiroideos/uso terapéutico , Enfermedad de Graves/tratamiento farmacológico , Enfermedad de Graves/radioterapia , Radioisótopos de Yodo/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Terapia Combinada , Femenino , Humanos , Radioisótopos de Yodo/farmacocinética , Masculino , Persona de Mediana Edad , Dosificación Radioterapéutica , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
AIM: We investigated whether additional application of "cold" iodine after therapy with radioiodine could result in a prolongation of the effective half life of iodine-131 and would thus lead to an increase of the effective thyroid radiation dose. METHODS: Time-activity-curves after therapy with radioiodine were analysed in 25 patients (16 women, 9 men). Nine patients suffered from autonomously functioning thyroid nodules, 5 from autonomous multinodular goiter and 11 from Graves' disease. These patients had an effective half life shorter than 4 days resulting in an undertreatment of > 20% with respect to the desired effective thyroid radiation dose. 2-4 days after therapy with radioiodine all patients received "cold" iodine for three days in a dose of 3 x 200 micrograms per day. RESULTS: In 14 of the 25 patients an increase of the effective half life was observed. Patients with an autonomously functioning thyroid nodule showed a mean increase of the effective thyroid radiation dose of 40 +/- 44 Gy, patients with toxic multinodular goiter of 29 +/- 30 Gy and patients with Graves' disease of 37 +/- 37 Gy. CONCLUSION: Additional application of "cold" iodine after therapy with radioiodine can prolong the effective half life in selected patients. We suspect a correlation with the thyroid iodine pool. This will be the basis for further investigations hopefully resulting in a better patient preselection to determine who might respond to this therapy.
Asunto(s)
Bocio Nodular/radioterapia , Enfermedad de Graves/radioterapia , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Yodo/uso terapéutico , Nódulo Tiroideo/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Semivida , Humanos , Yodo/farmacocinética , Masculino , Persona de Mediana Edad , Insuficiencia del Tratamiento , Resultado del TratamientoAsunto(s)
Adenocarcinoma Folicular/diagnóstico por imagen , Edema Encefálico/etiología , Radioisótopos de Yodo , Neoplasias Meníngeas/diagnóstico por imagen , Meningioma/diagnóstico por imagen , Neoplasias Primarias Secundarias/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico por imagen , Adenocarcinoma Folicular/patología , Anciano , Edema Encefálico/diagnóstico por imagen , Femenino , Humanos , Neoplasias Meníngeas/patología , Meningioma/patología , Metástasis de la Neoplasia , Neoplasias Primarias Secundarias/patología , Receptores de Somatostatina/análisis , Neoplasias de la Tiroides/patología , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
A 41-year-old male patient suffering from psoriasis arthropathica underwent a two-phase bone scan for activity of joint affections. Extensive diffuse skin contamination of the extremities in the delayed images was due to the use of the patient's own radioactive urine as an embrocation for psoriasis exanthema.